Ramurthy
Muthukumarappan Ramurthy, Commerce City, CO US
Patent application number | Description | Published |
---|---|---|
20100218941 | Determining the Use of Stimulation Treatments Based on High Process Zone Stress - Methods for determining whether to perform a stimulation treatment on a subterranean zone are disclosed. Process zone stress (“PZS”), indicative of a production potential of the subterranean zone, is determined, and a determination is made as to whether the PZS exceeds a preselected value. A PZS exceeding the preselected value may indicate a poor production potential, and a stimulation treatment of the subterranean zone may be avoided. As a result, a substantial cost saving associated with the avoided stimulation treatment may be realized. | 09-02-2010 |
Muthukumarappan Ramurthy, Greenwood Village, CO US
Patent application number | Description | Published |
---|---|---|
20150039235 | PERMEABILITY PREDICTION SYSTEMS AND METHODS USING QUADRATIC DISCRIMINANT ANALYSIS - Permeability prediction systems and methods using quadratic discriminant analysis are presented. At least one disclosed method embodiment includes: acquiring formation property measurements at a plurality of positions along at least one borehole in a study area; identifying clusters in a plurality of points representing the formation property measurements at the plurality of postions; and determining a system permeability value for each cluster. Quadratic Discriminant Analysis (“QDA”) is used to associate one the clusters with each position along the one or more boreholes, thereby determining a system permeability prediction for each position. The total system permeability can then be predicted by aggregating the system permeability predictions. | 02-05-2015 |
Savithri Ramurthy, Emeryville, CA US
Patent application number | Description | Published |
---|---|---|
20090170904 | Substituted benzimidazoles and methods of their use - New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer. | 07-02-2009 |
20100216767 | QUINAZOLINES FOR PDK1 INHIBITION - The invention provides novel compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions. | 08-26-2010 |
20160038504 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent. | 02-11-2016 |
Savithri Ramurthy US
Patent application number | Description | Published |
---|---|---|
20150274733 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics | 10-01-2015 |
Savithri Ramurthy, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20150274733 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof; as further described herein. The present invention further provides pharmaceutical compositions comprising these compounds, and combinations comprising these compounds combined with or used with a therapeutic co-agent, as well as therapeutic uses of these compounds and compositions. These are useful in the treatment of diseases such as cancer that are associated with activation of ERK1 and/or ERK2, and especially for MAPK pathway dependent cancers showing resistance to Raf and/or MEK inhibitory cancer therapeutics | 10-01-2015 |
Savithri Ramurthy, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20160038504 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent. | 02-11-2016 |